Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in AGA-positive NSCLC Post-TKI
NCT07158840Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07158840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158840.